Loading cancer entity…
Loading cancer entity…
Clinical trials
341 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03493152 | Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019) | no longer available | — | — | The University of Texas Health Science Center at San AntonioOTHER | 0 | May 28, 2025 | clinicaltrials |
| NCT01689376 | Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program) | no longer available | — | — | BayerINDUSTRY | 0 |
| Aug 16, 2016 |
| clinicaltrials |
| NCT01613053 | Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination(MACS2226) | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 24, 2015 | clinicaltrials |
| NCT01646593 | Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy | no longer available | — | — | BayerINDUSTRY | 0 | Dec 15, 2014 | clinicaltrials |
Data updated 22 days agoSource updated May 28, 2025source: clinicaltrials